Recombined chimeric antibody against human tumor necrosis factor alpha

A tumor necrosis factor, chimeric antibody technology, applied in the field of immunology, can solve problems such as attack

Active Publication Date: 2010-09-29
PHARMAB
View PDF21 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, these foreign antibodies may be attacked by host immune antibodies, with the result that they are neutralized before they can be effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombined chimeric antibody against human tumor necrosis factor alpha
  • Recombined chimeric antibody against human tumor necrosis factor alpha
  • Recombined chimeric antibody against human tumor necrosis factor alpha

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1 Production of anti-hTNFα mouse monoclonal antibody

[0084] Four-week-old BALB / c mice were subcutaneously injected with 20 μg of recombinant hTNFα (rhTNFα, purchased from PeproTech Inc.) in complete adjuvant. Five injections are given every three to four weeks. Finally, a single injection of 20 μg rhTNFα was given intraperitoneally. After serum testing, mice with high levels of anti-hTNFα antibody serum were identified. The mouse spleen was taken out and fused with the mouse myeloma Sp2 / O cell line. Mix 5×10 8 Sp2 / O cells with 5 × 10 8 Splenocytes were fused in a solution of 50% polyethylene glycol (PEG, molecular weight 1450) and 5% dimethylsulfoxide (DMSO). Use Iscove medium (containing 10% fetal bovine serum, 100 units / ml penicillin, 100 μg / ml streptomycin, 0.1 mM hypoxanthine, 0.4 μM aminopterin and 16 μg thymidine) to adjust the number of spleen cells to 7.5×10 5 / ml, add 0.2ml into the wells of 96-well culture plate. Place at 37°C 5% CO 2 in the ...

Embodiment 2

[0085] Qualitative Example 2 Anti-hTNFα murine antibody:

[0086] There are two assays for the characterization of anti-hTNFα antibodies. One method measures the competitive binding of the antibody to hTNFα for Humira, and the other method measures the ability of the antibody to neutralize hTNFα in a L929 cytotoxicity assay. The two methods and their experimental results are described respectively below.

[0087] 1. Competition Binding Assay with Humira Antibody

[0088] Horseradish peroxidase (HRP, Boehringer Manheim)-labeled anti-hTNFα human antibody Humira (Abbott) was used as a reagent. rhTNFα (50 μl, 0.05 μg / ml) was coated on a microtiter plate (CorningLife Sciences) and left overnight at room temperature. The coating solution was discarded, the wells were blocked with 1% skim milk dissolved in phosphate buffered saline (PBS) for 0.5 hours, and the wells were washed with PBS containing 0.05% Tween 20. Then, a mixture of 50 μl of growth medium (DMEM+5% FBS, Invitrogen)...

Embodiment 3

[0091] Example 3 Cloning of heavy chain and light chain of TM2-11-12 murine antibody

[0092] In order to express the C2-11-12 chimeric antibody, the DNA fragments encoding the heavy and light chain variable regions of the anti-hTNFα murine antibody TM2-11-12 must first be obtained. RNA was isolated from TM2-1112 mouse hybridoma cells using an RNA purification kit (Invitrogen Corp.) to prepare cDNA (GeneRacer kit, Invitrogen Corp.). The heavy chain was isolated from cDNA by polymerase chain reaction (PCR) using a 5' primer (5'CGACTGGAGCACGAGGACACTGA-3', SEQ ID NO: 11) and a 3' primer (5'TCCAGGGGCCAGTGGATAGACAGA-3', SEQ ID NO: 12) Variable region DNA fragments. The 3' primer is homologous and antisense to the mouse igG1 heavy chain constant region. These resulting DNA fragments were cloned into TOPO TA vector (Invitrogen) and sequenced. All heavy chain variable region clones showed the same nucleotide sequence (SEQ ID NO: 1). The nucleotide sequence and its encoded amino ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an antibody combined with human tumor necrosis factor Alpha (hTNF a), juxtaposing out antibody heavy chain and nucleotide sequence of light chain variable region, and the amino acid sequence derived from the nucleotide sequence. The heavy chain and the light china are connected into chimeric genes with the genes in the human immunoglobulin gamma 1(hIgG1) heavy china constant region and in the kappa (k) light chain constant region respectively, then the carrier with the chimeric genes is introduced into the host cell line expressing antibodies protein. The restructuringchimeric antibody protein is tested outside human body and can neutralize the hTNF Alpha activity. The invention is suitable for treating disease of excessive harmful hTNF Alpha secretion, comprisinga plurality of inflammations such as rheumatoid arthritis and regional enteritis.

Description

technical field [0001] The present invention relates to the field of immunology, especially the chimeric antibody and its application, specifically the recombinant chimeric antibody against human tumor necrosis factor alpha and its application. Background technique [0002] Human tumor necrosis factor alpha (hTNFα) is a cytokine produced by many cell types including macrophages, mast cells and lymphocytes. The biological activity of human TNFα conducts signal transduction through two different receptors (p55 and p75), and plays an important role in regulating inflammation and immune system. In various reports, it is believed that hTNFα is involved in the pathophysiology of many diseases, including sepsis, autoimmune diseases, transplant rejection, infectious diseases and intestinal disorders (see, e.g., Vasilli, P., Annu. Rev. Immunol. 10 : 411-452, 1992; Tracey, K., and Cerami, A., Annu. Rev. Med. 45: 491-503, 1994). Since hTNFα is deleterious in many ailments, antagonist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/525C07K19/00A61K38/19A61P35/00C12N15/13C12N15/63
Inventor 金宜慧孙乃超周若芸刘瑞贤
Owner PHARMAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap